Karuna bucks the neuro trend
The novel schizophrenia candidate KarXT will head to regulators after a win in Emergent-2.
Biotech’s important data reveals
Key upcoming clinical results approach in the third quarter for lecanemab, high-dose Eylea and Zimura.
Karuna seeks a novel schizophrenia mechanism
Pivotal data will show whether KarXT can walk the risk-benefit tightrope.
Biotech catalysts on the horizon
The second quarter should bring pivotal data for Karuna and key cardiomyopathy results for Alnylam, while Ionis's eplontersen lags in amyloidosis.
Biggest unpartnered assets: Argenx nears crunch time
Amid cautionary tales of other highly valued unpartnered assets, efgartigimod approaches its US date with destiny.
Neurocrine gets selective in schizophrenia
The group’s deal with Sosei will see it compete with Karuna and Cerevel.
Cerevel finds trial success as easy as ’231
Early stage schizophrenia data have seen the group double in value, but there are a couple of sticking points.
Biotech’s important clinical data readouts
The second quarter brings updates for Scholar Rock, Alnylam and Dicerna, among others.
2020 wins top of the froths for biotech stocks
It's official: dramatic share price jumps in response to clinical data have become more common.
